Aglatimagene besadenovec
Aglatimagene besadenovec is a gene pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
6606 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 743 | 1511 | 468 | 82 | 1781 | 4270 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 25 | 61 | 69 | 62 | 256 | 459 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 155 | 218 | 40 | 10 | 56 | 410 |
| Adenocarcinoma | D000230 | — | — | 44 | 132 | 22 | 1 | 80 | 259 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 69 | 30 | 13 | 4 | 79 | 182 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | 6 | 14 | 11 | 6 | 60 | 93 |
| Urinary bladder neoplasms | D001749 | — | C67 | 20 | 10 | 3 | 2 | 44 | 72 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 3 | 7 | 9 | 3 | 28 | 49 |
| Non-small-cell lung carcinoma | D002289 | — | — | 30 | 16 | — | 1 | 3 | 42 |
| Pain | D010146 | EFO_0003843 | R52 | 2 | 8 | 14 | 6 | 10 | 37 |
Show 40 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 120 | 73 | 20 | — | 105 | 290 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 24 | 12 | 5 | — | 42 | 79 |
| Colorectal neoplasms | D015179 | — | — | 31 | 14 | 3 | — | 37 | 76 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 38 | 17 | 2 | — | 18 | 64 |
| Head and neck neoplasms | D006258 | — | — | 17 | 5 | 1 | — | 19 | 39 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | 4 | 4 | — | 28 | 35 |
| Urologic neoplasms | D014571 | — | C64-C68 | 11 | 6 | 1 | — | 9 | 24 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 10 | 6 | 1 | — | 6 | 22 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 4 | 7 | 1 | — | 11 | 22 |
| Sarcoma | D012509 | — | — | 10 | 4 | 1 | — | 8 | 21 |
Show 40 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 27 | 8 | — | — | 18 | 47 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 17 | 5 | — | — | 9 | 29 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 13 | 4 | — | — | 14 | 29 |
| Esophageal neoplasms | D004938 | — | C15 | 10 | 6 | — | — | 13 | 25 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 13 | 4 | — | — | 7 | 21 |
| Glioblastoma | D005909 | EFO_0000515 | — | 11 | 8 | — | — | 6 | 20 |
| Colonic neoplasms | D003110 | — | C18 | 6 | 2 | — | — | 12 | 20 |
| Lymphoma | D008223 | — | C85.9 | 9 | 1 | — | — | 9 | 19 |
| Glioma | D005910 | EFO_0000520 | — | 9 | 2 | — | — | 4 | 15 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 11 | 13 |
Show 93 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sedentary behavior | D057185 | — | — | 1 | — | — | — | 5 | 6 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | — | — | — | 5 | 6 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | 3 | 4 |
| Nasopharyngeal neoplasms | D009303 | — | — | 2 | — | — | — | 2 | 4 |
| Male breast neoplasms | D018567 | — | — | 3 | — | — | — | 1 | 4 |
| Male urogenital diseases | D052801 | — | — | 1 | — | — | — | 2 | 3 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | — | — | — | — | 3 |
| Diagnostic imaging | D003952 | — | — | 3 | — | — | — | — | 3 |
| Hodgkin disease | D006689 | — | C81 | 2 | — | — | — | — | 2 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | — | — | — | 1 | 2 |
Show 39 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | — | — | 6 | 6 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 5 | 5 |
| Magnetic resonance imaging | D008279 | — | — | — | — | — | — | 5 | 5 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 3 | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 3 | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 3 | 3 |
| Therapeutics | D013812 | — | — | — | — | — | — | 3 | 3 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | — | — | 3 | 3 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 3 | 3 |
| Genetic predisposition to disease | D020022 | — | — | — | — | — | — | 3 | 3 |
Show 215 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aglatimagene besadenovec |
| INN | aglatimagene besadenovec |
| Description | Aglatimagene besadenovec is a gene pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Gene |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544993 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 5Z72SSS34W (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 922 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use